Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes

Executive Summary

Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but a negative JAMA editorial is another knock on the PCSK9 inhibitor class.

You may also be interested in...



New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value

Already outdated? The latest ACC/AHA guidelines say at mid-2018 list prices, PCSK9 injectables are of low value, but the costs have plummeted since then.

PCSK9 Pick-Me-Up: New Cholesterol Guidelines May Mean Lower LDL Targets

Sales of PCSK9 inhibitors have been improving, though are still low, and inclusion of lower LDL-C targets in practice guidelines coming this November would be a boost.

Praluent Pricing: Collaboration With ICER Sets A New Standard

Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel